Everand Logo

Welcome to Everand!

  • STAT

    LISTEN: A lesson in startup jargon, pharma’s bare Alzheimer’s cupboard, and the cost of CAR-T

    How much is a shot at curing cancer worth? And what on Earth is an "oversubscribed Series A round"? Find out on this episode of our biotech podcast, "The Readout…
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Aug 16, 2018 1 minute

    How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer’s disease? And what on Earth is an “oversubscribed

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks